MNG553
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.735
- INFLAMMATORY_RESPONSE+0.624
- IL6_JAK_STAT3_SIGNALING+0.586
- ALLOGRAFT_REJECTION+0.565
- ANDROGEN_RESPONSE+0.504
- ANGIOGENESIS+0.504
- INTERFERON_GAMMA_RESPONSE+0.500
- COAGULATION+0.484
- COMPLEMENT+0.478
- HYPOXIA+0.478
Top 10 suppressed
- DNA_REPAIR-0.379
- E2F_TARGETS-0.369
- MITOTIC_SPINDLE-0.279
- G2M_CHECKPOINT-0.195
- PROTEIN_SECRETION-0.134
- WNT_BETA_CATENIN_SIGNALING-0.127
- BILE_ACID_METABOLISM-0.087
- SPERMATOGENESIS-0.064
- PEROXISOME-0.038
- UNFOLDED_PROTEIN_RESPONSE-0.012
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR33532823 | — | C | 0.933 |
| 2 | SRR1347688 | GTEX | — | 0.927 |
| 3 | SRR1323196 | GTEX | — | 0.910 |
| 4 | s_150324_4b | EPN | Posterior Fossa EPN | 0.903 |
| 5 | MNG639 | — | — | 0.902 |
| 6 | SRR26320076 | — | — | 0.902 |
| 7 | MNG281 | — | — | 0.902 |
| 8 | EPT0509 | EPN | EPN Tumor | 0.899 |
| 9 | EPT0508 | EPN | Posterior Fossa EPN | 0.899 |
| 10 | SRR1335688 | GTEX | — | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.735 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.624 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.586 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.565 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.504 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.504 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| COAGULATION | 0.484 | Binimetinib | — uncovered |
| COMPLEMENT | 0.478 | Inavolisib | — uncovered |
| HYPOXIA | 0.478 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.473 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.471 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.470 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.463 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.446 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.427 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.420 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.404 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.350 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.325 | Inavolisib | — uncovered |